Promethera Biosciences completes €39,7 million ($44,4 million) Series D financing

Proceeds will support ongoing clinical…

Complete transaction creating Nasdaq-listed company targeting chronic inflammatory and autoimmune diseases

– Developing Oral Therapies with…